Peptides: Separating Regulation from Marketing

Peptides attract more confident claims per unit of evidence than almost anything else in this field. Some of that enthusiasm is founded; a great deal of it is not; and the most useful thing to understand first is the regulatory structure, because it determines what can legitimately reach you regardless of what the science eventually shows.

What a peptide is

A peptide is a short chain of amino acids. Proteins are long chains of the same building blocks; peptides are the short ones, conventionally under about fifty residues. Many of the body's own signalling molecules are peptides — insulin, glucagon, growth hormone-releasing hormone, oxytocin. This is worth stating because "peptide" is not a category of drug, any more than "molecule" is. It describes chemical structure, not mechanism, and certainly not efficacy. Two peptides may have nothing in common beyond being short amino acid chains. Marketing that treats peptides as a class with shared properties is not making a scientific claim.

Peptides that are approved medicines

Several peptide drugs hold FDA approval for specific indications and are unremarkable parts of clinical practice. Insulin is a peptide. So are the GLP-1 receptor agonists. So are teriparatide for osteoporosis, leuprolide in oncology and endocrinology, and octreotide for acromegaly. These went through the approval process. They have labelling, established dosing, characterised adverse effects, and a manufacturer who is accountable for each batch.

Peptides that are not

The peptides that dominate online discussion — BPC-157, TB-500, various growth hormone secretagogues — are in a different position. They have no FDA-approved indication. The human clinical evidence for most is limited or absent, with much of the frequently cited data coming from animal studies. There are no standardised protocols, because standardisation follows from trials that have not been done. That does not make them worthless as research subjects. It does mean that anyone asserting a specific outcome from one of them is going beyond what the evidence supports.

The compounding lists are the practical constraint

Here is the part most discussion skips. A compounding pharmacy may not compound whatever it likes. Bulk drug substances used in compounding must meet criteria set out in federal law, and the FDA maintains categories governing which substances are eligible. The position here moved twice in 2026, and most of what is written online predates the change. In late 2023 the FDA placed a number of peptides into Category 2 — substances the agency had identified as raising significant safety risks. BPC-157 was among them, and while it sat there, compounding it was effectively prohibited. In April 2026 the FDA removed twelve peptides from Category 2, BPC-157 and TB-500 among them. That is the fact the headlines seized on, and it is where most articles stop. It should not be read as permission. Category 2 is the prohibited list; the 503A positive list is the permitted one, and removal from the first does not add a substance to the second. These twelve landed in between — no longer prohibited, not authorised. In July 2026 the Pharmacy Compounding Advisory Committee reviewed seven of them and voted six onto the 503A list, rejecting only Emideltide (DSIP). The margins were narrow — BPC-157, KPV and TB-500 each cleared 8–6 — and the committee voted against the FDA's own staff position. Crucially, a PCAC vote is a recommendation, not a rule. The FDA has not acted on it, doing so requires formal rulemaking that ordinarily takes a year or more, and nothing about a substance's legal status changed on the day of the vote. So the honest position today: these peptides are out of Category 2, recommended by an advisory committee, and still not on the list that would let a 503A pharmacy compound them. A pharmacy dispensing one now is not operating in a settled framework, whatever the headlines implied. If the rulemaking completes, that changes — plausibly during 2027. This is why the gap between what is discussed online and what a legitimate clinical service can actually offer stays wide even after apparently good news. It is not that clinicians are behind the curve. It is that "no longer banned" and "allowed" are different states, and only one of them lets a pharmacy dispense.

What a laboratory-supply label actually signals

A large grey market sells peptides under a laboratory-supply label, marked as not for human consumption. That label is doing real work, and it is not a formality that everyone winks at. Material sold this way is not dispensed by a licensed pharmacy, is not prepared for administration to people, and carries no assurance of identity, purity or sterility. Independent testing of this market has repeatedly found products that were underdosed, mislabelled, contaminated, or not the substance claimed. Nothing about the supply chain is designed to produce something you should inject. The distinction between a prescribed preparation and a research chemical is not marketing. It is the difference between a licensed pharmacist preparing a named patient's medication under state board oversight, and an unregulated seller shipping a vial.

How to evaluate a claim

When you encounter an assertion about a peptide, three questions separate signal from noise. Is the evidence human? A great many peptide claims trace back to rodent studies. Animal results are how research starts; they are not how it concludes. Doses in animal studies also frequently do not scale to anything a person would take. Is the outcome measured or reported? Studies measuring an objective endpoint are a different class of evidence from surveys of how participants felt. Who is making the claim, and do they sell it? Not disqualifying, but it belongs in your assessment.

What a legitimate service can offer

A clinical service can evaluate you, order appropriate laboratory work, and prescribe what a licensed provider judges appropriate from what a licensed pharmacy may legally dispense. That set is narrower than the internet's, and it will stay narrower. A provider who tells you a peptide you have read about cannot be prescribed is not being unhelpful — they are telling you where the line is. Be wary of the opposite. A service willing to supply anything you ask for is telling you something about its relationship with the rules that should make you consider what else it is willing to skip.